According to veteran CEO Paul Hastings, the most significant industry change was when the FDA, under Janet Woodcock, began valuing patient outcomes over academic indices. This forced companies to finally prioritize the patient's voice in drug development and approval.

The trend toward fewer FDA advisory committee (AdCom) meetings is a mistake. AdComs force scientific debate into the open, providing a transparent check against the "my way or the highway" approach of powerful agency figures. Public hearings ensure regulatory decisions reflect a broader consensus, not just internal biases.

The system's over-reliance on a few large academic centers in major cities creates a massive bottleneck. Paul Hastings argues for empowering community-based research centers where most patients live to dramatically increase enrollment speed, diversity, and US competitiveness.

A critical disconnect exists in drug development: the decision to start a trial is most influenced by the number of academic publications on a target. However, this metric has no bearing on the trial's likelihood of success. The best predictor of success is actually strong human genetic evidence linking the target to the disease.

Despite the FDA leadership co-authoring an editorial supporting single-trial approvals, the industry is skeptical. The agency's recent inconsistent actions mean no executive or investor can confidently build a development strategy or financial model based on this policy, rendering the announcement largely ineffective.

Our ability to generate and test therapeutic hypotheses in silico is rapidly outpacing the slow, expensive conventional clinical trial system. Without regulatory reform, the pipeline of promising drugs will remain stuck, preventing breakthroughs from reaching patients. The science is solvable; the system is not.

To solve patient enrollment bottlenecks, biotech companies should directly support and utilize community-based medical centers where 95% of patients receive care. These local clinics are a more accessible and efficient alternative to large, bureaucratic academic institutions.

The focus on Vinay Prasad's personality misses the larger institutional crisis at the FDA: a shift from large, team-based scientific reviews to centralized, politically-influenced decisions made by a few individuals. This 'picking winners and losers' approach undermines the agency's scientific integrity, regardless of who is in charge.

Martin Varsavsky argues the FDA's core mandate, stemming from a century ago to prevent poisonings, is misaligned with modern medicine. It prioritizes avoiding any potential harm from a new treatment over the potential to save lives, especially for patients with grim alternatives.